On December 15, 2025, Telomir Pharmaceuticals approved $400,000 in short-term incentives for CEO Erez Aminov and a potential $150,000 milestone payout contingent on FDA IND acceptance, alongside a base salary adjustment to $500,000 effective January 1, 2026.